BR112022018766A2 - Formulações de anticorpo de protofibrila anti-ass de concentração alta e métodos de uso das mesmas - Google Patents

Formulações de anticorpo de protofibrila anti-ass de concentração alta e métodos de uso das mesmas

Info

Publication number
BR112022018766A2
BR112022018766A2 BR112022018766A BR112022018766A BR112022018766A2 BR 112022018766 A2 BR112022018766 A2 BR 112022018766A2 BR 112022018766 A BR112022018766 A BR 112022018766A BR 112022018766 A BR112022018766 A BR 112022018766A BR 112022018766 A2 BR112022018766 A2 BR 112022018766A2
Authority
BR
Brazil
Prior art keywords
methods
high concentration
ass
antibody formulations
protofibril antibody
Prior art date
Application number
BR112022018766A
Other languages
English (en)
Inventor
Yoshida Nobuo
Sakuramoto Naomi
Sakaguchi Takahisa
Kito Hirokazu
Ozawa Takahiro
Joshi Anjali
Yueh Hsu Yung
Souillac Pierre
Original Assignee
Eisai R&D Man Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eisai R&D Man Co Ltd filed Critical Eisai R&D Man Co Ltd
Publication of BR112022018766A2 publication Critical patent/BR112022018766A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39591—Stabilisation, fragmentation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/133—Amines having hydroxy groups, e.g. sphingosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Dermatology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Psychiatry (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Cosmetics (AREA)
  • Peptides Or Proteins (AREA)

Abstract

FORMULAÇÕES DE ANTICORPO DE PROTOFIBRILA ANTI-Aß DE CONCENTRAÇÃO ALTA E MÉTODOS DE USO DAS MESMAS. São fornecidas no presente documento formulações farmacêuticas aquosas que compreendem altas concentrações de um anticorpo de protofibrila anti-Aß isolado ou um fragmento do mesmo que se liga às protofibrilas de Aß humanas, como BAN2401, arginina, polissorbato 80 e um tampão farmaceuticamente aceitável.
BR112022018766A 2020-03-20 2021-03-19 Formulações de anticorpo de protofibrila anti-ass de concentração alta e métodos de uso das mesmas BR112022018766A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202062992746P 2020-03-20 2020-03-20
US202063027263P 2020-05-19 2020-05-19
PCT/IB2021/000155 WO2021186245A1 (en) 2020-03-20 2021-03-19 HIGH CONCENTRATION ANTI-Aß PROTOFIBRIL ANTIBODY FORMULATIONS AND METHODS OF USE THEREOF

Publications (1)

Publication Number Publication Date
BR112022018766A2 true BR112022018766A2 (pt) 2022-11-01

Family

ID=75746958

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112022018766A BR112022018766A2 (pt) 2020-03-20 2021-03-19 Formulações de anticorpo de protofibrila anti-ass de concentração alta e métodos de uso das mesmas

Country Status (14)

Country Link
US (1) US20230183328A1 (pt)
EP (2) EP4252777A3 (pt)
JP (1) JP2023518066A (pt)
KR (1) KR20220156534A (pt)
CN (1) CN115315251A (pt)
AU (1) AU2021238951A1 (pt)
BR (1) BR112022018766A2 (pt)
CA (1) CA3174778A1 (pt)
CL (1) CL2022002517A1 (pt)
CO (1) CO2022012916A2 (pt)
IL (1) IL295383A (pt)
MX (1) MX2022011101A (pt)
TW (1) TW202200201A (pt)
WO (1) WO2021186245A1 (pt)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL300059A (en) 2020-07-23 2023-03-01 Othair Prothena Ltd Anti-Abata antibodies
EP4367516A1 (en) 2021-07-09 2024-05-15 Eisai R&D Management Co., Ltd. Biomarkers for alzheimer's disease treatment
TW202339794A (zh) 2022-02-02 2023-10-16 日商衛材R&D企管股份有限公司 使用ｐ—ｔａｕ１８１水平之治療方法
WO2024118665A1 (en) 2022-11-28 2024-06-06 Eisai R&D Management Co., Ltd. Methods of treatment using a tau pet level

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112805031A (zh) * 2018-07-24 2021-05-14 卫材R&D管理有限公司 阿尔茨海默病的治疗及预防方法

Also Published As

Publication number Publication date
MX2022011101A (es) 2022-10-03
TW202200201A (zh) 2022-01-01
CN115315251A (zh) 2022-11-08
JP2023518066A (ja) 2023-04-27
AU2021238951A1 (en) 2022-10-20
CA3174778A1 (en) 2021-09-23
EP4252777A2 (en) 2023-10-04
CL2022002517A1 (es) 2023-03-24
KR20220156534A (ko) 2022-11-25
WO2021186245A1 (en) 2021-09-23
EP4121007A1 (en) 2023-01-25
US20230183328A1 (en) 2023-06-15
EP4252777A9 (en) 2024-03-06
CO2022012916A2 (es) 2022-09-20
EP4252777A3 (en) 2024-01-24
IL295383A (en) 2022-10-01

Similar Documents

Publication Publication Date Title
BR112022018766A2 (pt) Formulações de anticorpo de protofibrila anti-ass de concentração alta e métodos de uso das mesmas
CY1126062T1 (el) Σταθερη φαρμακοτεχνικη μορφη anti-ifnar1
BR112017024517A2 (pt) compostos de tetraidroquinolinona como moduladores ror gama
BRPI0617664B8 (pt) uso de um anticorpo que reconhece a il-6 para a produção de uma composição farmacêutica para tratar o enfarte do miocárdio ou suprimir a remodelagem ventricular esquerda depois do enfarte do miocárdio
BR112023015045A2 (pt) Agonistas de receptores de gpcr, composições farmacêuticas que compreendem os mesmos e métodos para seu uso
BR112015022934A8 (pt) esteróides neuroativos, composições e usos destes
BRPI0516299B8 (pt) formulação farmacêutica e uso de uma formulação farmacêutica
EA200400242A1 (ru) Фармацевтические композиции, содержащие бета-лапахон или его производные или аналоги, и способы их применения
BR112022016456A2 (pt) Formulações de anticorpos anti-tslp humanos e métodos de uso dos mesmos
BR112017011552A2 (pt) derivados de fgf21 e seu uso
BR112017005801A2 (pt) anticorpo capaz de neutralizar a substância tendo atividade alternativa para função de fator de coagulação viii (fviii)
BR112022011032A2 (pt) Conjugado de anticorpo-fármaco anti-claudina e uso farmacêutico do mesmo
BR112021018707A2 (pt) Formulações compreendendo melflufeno
BR112021019950A2 (pt) Métodos de esgotamento de agentes causadores de doenças por meio de anticorpo de fagocitose alvejada
BR112022004397A2 (pt) Composições para tratamento bucal que compreendem beta ácidos de lúpulo e aminoácidos
ECSP21060917A (es) Formulación de anticuerpos terapéuticos
BR112021014854A2 (pt) Tratamento de lesões de pele e prurido em pacientes com prurigo nodularisis
BRPI0518619A2 (pt) mÉtodo de tratar cÂncer em um mamÍfero, combinaÇço farmacÊutica, uso de uma composiÇço ou combinaÇço farmacÊutica e composiÇço imunogÊnica
BR112023024433A2 (pt) Análogos, conjugados e métodos de uso de camptotecina
NO20050216L (no) Steroidkonjugater samt fremstilling og anvendelse derav
BR112021025394A2 (pt) Derivados de antraciclina, conjugados de fármaco e molécula de ligação ao alvo, uso de conjugado de fármaco e molécula de ligação ao alvo, método de tratamento de uma doença em um paciente em necessidade de tratamento, e composição farmacêutica
AR117607A1 (es) Formulaciones de anticuerpo líquidas de alta concentración
BR112023002724A2 (pt) Neoantígenos ras e seus usos
CO2021009025A2 (es) Proteínas de unión multiespecíficas basadas en pseudofab
BR112022009563A2 (pt) Compostos de pirrolotriazina atuando como inibidor de mnk